Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | PREP | P48147 | 3/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CETP | P11597 | 2/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL518234 | 0.81 | MME (0.39) | MMEKMT2AMEN1CETPEPHX1 | |
| SCHEMBL6470515 | 0.80 | MME (0.35) | MMEKMT2AMEN1CETPEPHX1 | |
| SCHEMBL4991851 | 0.78 | SLC6A2 (0.39) | PARP1PREPOPRK1SLC6A2SLC6A4 | |
| SCHEMBL5538602 | 0.75 | MME (0.39) | MMEKMT2AMEN1CETP | |
| SCHEMBL535200 | 0.75 | CYP2D6 (0.38) | MMEKMT2AMEN1EPHX1SLC6A3 | |
| SCHEMBL2432098 | 0.74 | CYP1A2 (0.53) | KMT2AMEN1OPRK1 | |
| Hydrochloric Acid SCHEMBL6926712 | 0.74 | MME (0.39) | MMEKMT2AMEN1CETP | |
| SCHEMBL2432526 | 0.74 | CYP1A2 (0.53) | KMT2AMEN1OPRK1 | |
| SCHEMBL5695495 | 0.73 | USP19 (0.38) | PARP1PREPCTSLOPRK1SLC6A2 | |
| SCHEMBL2913177 | 0.72 | AKR1C1 (0.34) | KMT2AMEN1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | HCRTR2, MCHR1, MCHR2 | MME 1593/4885PARP1 2979/4885PREP 2647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.